Expanding on Abraxane Safety: Temporal Insights and Future Directions for Adverse Event Analysis [Letter]
Fangcai Yang,1 Wukun Ge2 1Department of Clinical Nutrition, Ninghai First Hospital, Ningbo, Zhejiang, 315600, People’s Republic of China; 2Department of Clinical Pharmacy, Ninghai First Hospital, Ningbo, Zhejiang, 315600, People’s Republic of ChinaCorrespondence: Wukun Ge, Depart...
Saved in:
Main Authors: | Yang F, Ge W |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2025-02-01
|
Series: | International Journal of Nanomedicine |
Subjects: | |
Online Access: | https://www.dovepress.com/expanding-on-abraxane-safety-temporal-insights-and-future-directions-f-peer-reviewed-fulltext-article-IJN |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01) -
A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01) -
Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
by: Qun Li, et al.
Published: (2025-02-01) -
Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01) -
The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01)